(Q21957029)

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Clinical practice. Acute infectious diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Guidelines for the management of inflammatory bowel disease in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Course of ulcerative colitis: analysis of changes in disease activity over years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Changes in extent of ulcerative colitis: a study on the course and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Once-daily, high-concentration MMX mesalamine in active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Sulphasalazine and salicylazosulphadimidine in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Cortisone in ulcerative colitis; final report on a therapeutic trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Intensive intravenous regimen for severe attacks of ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Azathioprine in ulcerative colitis: final report on controlled therapeutic trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Randomised controlled trial of azathioprine withdrawal in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial man

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Review article: systemic and topical steroids in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Acute surgical emergencies in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Current concepts and controversies in surgery for IBD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Management of Crohn's disease in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Disease activity courses in a regional cohort of Crohn's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Long-term evolution of disease behavior of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Low dose steroids and clinical relapse in Crohn's disease: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Use of an intravenous steroid regimen in the treatment of acute Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Double blind, placebo controlled trial of metronidazole in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Methotrexate for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

The effectiveness of budesonide therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

1 reference

7 January 2021

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

RDP58 is a novel and potentially effective oral therapy for ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

AGA technical review on perianal Crohn’s disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Onercept for Moderate-to-Severe Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Anti-interleukin-12 antibody for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Natalizumab for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Sargramostim for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A preliminary study of growth hormone therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Fertility and pregnancy in the patient with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Cancer risk in patients with inflammatory bowel disease: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

10.1016/S0140-6736(07)60751-X

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

114937

114937

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference